TY - JOUR
T1 - Acceptance & Commitment Therapy for Adults Living with Inflammatory Bowel Disease and Distress
T2 - A Randomized Controlled Trial
AU - Naude, Colette
AU - Skvarc, David
AU - Maunick, Bernadette
AU - Evans, Subhadra
AU - Romano, Daniel
AU - Chesterman, Susan
AU - Russell, Lahiru
AU - Dober, Madeleine
AU - Fuller-Tyszkiewicz, Matthew
AU - Gearry, Richard
AU - Gibson, Peter R.
AU - Knowles, Simon
AU - McCombie, Andrew
AU - Eric, O.
AU - Raven, Leanne
AU - Van Niekerk, Leesa
AU - Mikocka-Walus, Antonina
N1 - Publisher Copyright:
Copyright © 2024 The Author(s).
PY - 2025/8
Y1 - 2025/8
N2 - Background:The bidirectional relationship between disease activity and mental health in inflammatory bowel disease (IBD) has prompted investigations into the efficacy of psychotherapeutic interventions such as Acceptance & Commitment Therapy (ACT) on biopsychosocial outcomes. We aimed to examine the efficacy of an ACT Program (intervention) in comparison to a CBT-Informed Psychoeducation Program (active control) for individuals with IBD and co-existent psychological distress. Both programs were delivered online via a hybrid format (i.e.Therapist led and participant-led sessions).Methods:120 adults with IBD were randomized to either the intervention (N=61) or active control groups (N=59). Efficacy was determined using Linear Mixed Models for group differences, in rate of changes in study outcomes, between baseline, post intervention, and 3-month follow-up.Results:The primary outcome HRQoL significantly improved in the intervention group when compared with the active control group, with a significantly different rate of change observed from baseline to post intervention (t [190] = 2.15, p = 0.033) in favor of the intervention group with a medium effect size (β = 0.41, MD = 0.07, 95%CI [0.01, 0.12], p = 0.014). Similarly, the secondary outcome Crohn's disease activity significantly reduced in the intervention group when compared with the active control group, with a significantly different rate of change observed from baseline to 3-month follow-up (t [90] =-2.40, p = 0.018) in favor of the intervention group with a large effect size (β =-0.77, MD =-9.43, 95%CI [-13.72,-5.13], p < 0.001) p = 0.014). Further, when observing the rate of change in outcomes over time for the groups separately, anxiety symptoms and pain significantly improved in the intervention group only, and conversely, ulcerative colitis activity and stress symptoms significantly improved in the active control group only. All other outcomes (N=14) significantly improved over time in both groups including IBD activity, gastrointestinal unhelpful thinking patterns, visceral anxiety, fatigue interference, fatigue severity, fatigue frequency, psychological inflexibility, self-efficacy, resilience, current health status, depression symptoms, IBD control, and pain catastrophizing, however these changes were not significantly different between the groups.Conclusion:Both programs were of benefit to people with IBD and distress. However, ACT offers a significant added benefit for HRQoL and self-reported Crohn's disease activity and may be a useful adjuvant therapy in integrated IBD care.
AB - Background:The bidirectional relationship between disease activity and mental health in inflammatory bowel disease (IBD) has prompted investigations into the efficacy of psychotherapeutic interventions such as Acceptance & Commitment Therapy (ACT) on biopsychosocial outcomes. We aimed to examine the efficacy of an ACT Program (intervention) in comparison to a CBT-Informed Psychoeducation Program (active control) for individuals with IBD and co-existent psychological distress. Both programs were delivered online via a hybrid format (i.e.Therapist led and participant-led sessions).Methods:120 adults with IBD were randomized to either the intervention (N=61) or active control groups (N=59). Efficacy was determined using Linear Mixed Models for group differences, in rate of changes in study outcomes, between baseline, post intervention, and 3-month follow-up.Results:The primary outcome HRQoL significantly improved in the intervention group when compared with the active control group, with a significantly different rate of change observed from baseline to post intervention (t [190] = 2.15, p = 0.033) in favor of the intervention group with a medium effect size (β = 0.41, MD = 0.07, 95%CI [0.01, 0.12], p = 0.014). Similarly, the secondary outcome Crohn's disease activity significantly reduced in the intervention group when compared with the active control group, with a significantly different rate of change observed from baseline to 3-month follow-up (t [90] =-2.40, p = 0.018) in favor of the intervention group with a large effect size (β =-0.77, MD =-9.43, 95%CI [-13.72,-5.13], p < 0.001) p = 0.014). Further, when observing the rate of change in outcomes over time for the groups separately, anxiety symptoms and pain significantly improved in the intervention group only, and conversely, ulcerative colitis activity and stress symptoms significantly improved in the active control group only. All other outcomes (N=14) significantly improved over time in both groups including IBD activity, gastrointestinal unhelpful thinking patterns, visceral anxiety, fatigue interference, fatigue severity, fatigue frequency, psychological inflexibility, self-efficacy, resilience, current health status, depression symptoms, IBD control, and pain catastrophizing, however these changes were not significantly different between the groups.Conclusion:Both programs were of benefit to people with IBD and distress. However, ACT offers a significant added benefit for HRQoL and self-reported Crohn's disease activity and may be a useful adjuvant therapy in integrated IBD care.
KW - Acceptance and Commitment Therapy
KW - ACT
KW - Crohn's Disease
KW - IBD
KW - Inflammatory Bowel Disease
KW - Randomized Controlled Trial
KW - RCT
KW - Ulcerative Colitis
UR - https://www.scopus.com/pages/publications/85201765954
U2 - 10.14309/ajg.0000000000003032
DO - 10.14309/ajg.0000000000003032
M3 - Article
C2 - 39162706
AN - SCOPUS:85201765954
SN - 0002-9270
VL - 120
SP - 1839
EP - 1851
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 8
ER -